The clinical study investigating the effect of pemafibrate administration on cardiac diastolic function in patients with type 2 diabetes

Not Applicable

• Conditions: Type 2 diabetes, Dyslipidemia

• Registration Number: JPRN-UMIN000041707
• Lead Sponsor: Yamaguchi University, Graduate School of Medicine, Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Department of Bio-Signal Analysis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-23
• Study Completion: 2023-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1) Who has a history of fibrate exposure within 6 months. 2) Who suffers from atrial fibrillation. 3) Who is judged by the investigators to be inappropriate for this study.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
eft ventricular inflow blood velocity waveform (before versus 8-16 weeks after pemafibrate administration)

Secondary Outcome Measures

Name	Time	Method
Mitral annulus TDI, Pulmonary blood flow pressure waveform, AST, ALT, ALP, gammaGTP, Triglyceride, Free Fatty Acid, BNP(before versus 8-16 weeks after pemafibrate administration)